Walleye Capital’s Celldex Therapeutics CLDX Stock Holding History

Walleye Capital’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3,000	Closed	-$77.6K	–	4627
2025 Q3	$77.6K	Buy	+3,000	New	+$69.5K	﹤0.01%	3834
2024 Q3	–	Sell	-9,100	Closed	-$337K	–	5362
2024 Q2	$337K	Buy	9,100 +7,600	+507%	+$287K	﹤0.01%	3874
2024 Q1	$63K	Sell	1,500 -12,100	-89%	-$497K	﹤0.01%	4596
2023 Q4	$539K	Buy	13,600 +12,800	+1,600%	+$376K	﹤0.01%	2893
2023 Q3	$22K	Sell	800 -300	-27%	-$9.4K	﹤0.01%	4367
2023 Q2	$37.3K	Buy	+1,100	New	+$37.1K	﹤0.01%	3692
2023 Q1	–	Sell	-400	Closed	-$17.8K	–	3973
2022 Q4	$17.8K	Buy	+400	New	+$14.3K	﹤0.01%	2678

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Walleye Capital's CLDX Position: Q2 2026 in Review

Walleye Capital sold out of Celldex Therapeutics (CLDX) in Q2 2026, closing a stake of 8,147 shares — an estimated $258K sold.

Walleye Capital first reported a position in CLDX in Q4 2021 and held it in 12 quarters. The position peaked at $6.71M in Q4 2023. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Walleye Capital reported no remaining Celldex Therapeutics position as of Q2 2026 after selling out during the quarter.
Walleye Capital sold 8,147 Celldex Therapeutics shares in Q2 2026, an estimated $258K.
Walleye Capital first reported a position in Celldex Therapeutics in Q4 2021 and held it in 12 quarters.
Walleye Capital's Celldex Therapeutics position peaked at $6.71M in Q4 2023.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.